Table 2.
Clinical sensitivity of SARS-CoV-2 IgM and SARS-CoV-2 IgG.
| Days | Number of samples | SRAS-CoV-2 IgM | SRAS-CoV-2 IgG | ||||||
|---|---|---|---|---|---|---|---|---|---|
| N | P | Clin Sen (%) | 95% CI | N | P | Clin Sen (%) | 95% CI | ||
| <7 days | 12 | 3 | 9 | 75.00 | (46.8%, 91.1%) | 2 | 10 | 83.33 | (55.2%, 95.3%) |
| 7–14 days | 25 | 3 | 22 | 88.00 | (70.0%, 95.8%) | 0 | 25 | 100.00 | (86.7%, 100.0%) |
| >14 days | 31 | 2 | 29 | 93.55 | (79.3%, 98.2%) | 0 | 31 | 100.00 | (89.0%, 100.0%) |
| Total | 68 | 8 | 60 | 88.24 | (78.5%, 93.9%) | 2 | 66 | 97.06 | (89.9%, 99.2%) |
Days: days since the onset of symptoms; N: negative; P: positive; Clin Sen: clinical sensitivity.